Fig. 2: Berzosertib enhanced the antineoplastic effects of ionizing irradiation in DMG cell lines in short-term assays.

Results from proliferation assays of DMG cell lines treated with 10-12 concentrations of berzosertib and 0, 2 or 4 Gy. 72 h after treatment proliferation was measured with CellTiter-Glo. Exemplary proliferation assays for the three tested cell lines SU-DIPG-17 (A) SU-DIPG-24 (B) and SU-DIPG-33 (C). Proliferation was normalized to control without berzosertib for 0, 2 or 4 Gy separately. IC20 and IC50 values were derived from nonlinear regression of dose-response curves as described in Materials and Methods. Bliss-Synergy score 3D plots for SU-DIPG-17 (D) SU-DIPG-24 (E) and SU-DIPG-33 (F). Red color/value above 10 indicates a high probability of synergism, whereas values below -10 indicate antagonism and values between -10 and 10 indicate an additive effect. Overall Bliss scores and color scales are depicted below each plot. G IC50 overview of DMG cell lines (SU-DIPG-17: 0 Gy: 1526 nM, 2 Gy: 542.6 nM, 4 Gy: 463,6 nM; SU-DIPG-24: 0 Gy: 1390 nM, 2 Gy: 575.2 nM, 4 Gy: 492.6 nM; SU-DIPG-33: 0 Gy: 631.8 nM, 2 Gy: 468.6 nM, 4 Gy: 359.7 nM). Error bars show standard deviation. Statistical analysis was performed using one-way ANOVA comparison and with following Tukey-test. ns not significant (p > 0.05), *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Parentheses above bars indicate significance between compared groups.